Dr. Argilés on BRAF-Mutations in Colorectal Cancer

Guillem Argiles, MD
Published: Friday, Jul 10, 2015




Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 
SELECTED
LANGUAGE



Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x